Bristol-Myers’ opdivo approved in Europe for urothelial carcinoma
Bristol-Myers Squibb’s Opdivo (nivolumab) has been approved by the European Commission (EC) for the treatment of locally advanced unresectable or metastatic urothelial carcinoma (mUC) in adults after failure of prior platinum-based therapy.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.